Ironwood Pharmaceuticals Inc (IRWD)

16.87
0.25 1.46
NASDAQ : Health Care
Prev Close 17.12
Open 17.12
Day Low/High 16.39 / 17.49
52 Wk Low/High 7.35 / 14.35
Volume 1.39M
Avg Volume 1.22M
Exchange NASDAQ
Shares Outstanding 146.22M
Market Cap 2.51B
EPS -1.00
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Ironwood Pharmaceuticals Reaches Analyst Target Price

Ironwood Pharmaceuticals Reaches Analyst Target Price

In recent trading, shares of Ironwood Pharmaceuticals Inc. have crossed above the average analyst 12-month target price of $16.25, changing hands for $16.38/share.

Ironwood Pharmaceuticals To Host Fourth Quarter And Full-Year 2016 Investor Update Call

Ironwood Pharmaceuticals To Host Fourth Quarter And Full-Year 2016 Investor Update Call

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced it will host its fourth quarter and full-year 2016 investor update conference call and webcast at 4:30 p.

Premarket Biotech Movers: Ironwood Pharmaceuticals, Rigel Pharmaceuticals, FibroGen

Premarket Biotech Movers: Ironwood Pharmaceuticals, Rigel Pharmaceuticals, FibroGen

Ironwood Pharmaceuticals, Rigel Pharmaceuticals and FibroGen were among the biotech stock movers in premarket trading on Monday.

Synergy Pharmaceuticals Secures Approval for Linzess Competitor

Synergy Pharmaceuticals Secures Approval for Linzess Competitor

New bowel drug Trulance will be available for patients later this quarter.

Ironwood Pharmaceuticals Demonstrates Strong Execution On Strategy To Build Top-Performing Commercial Biotech

Ironwood Pharmaceuticals Demonstrates Strong Execution On Strategy To Build Top-Performing Commercial Biotech

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) today detailed strong execution against its strategy of building a top-performing commercial biotechnology company generating rapid, sustainable, high-margin growth.

Ironwood Pharmaceuticals Appoints Amy Schulman To Board Of Directors

Ironwood Pharmaceuticals Appoints Amy Schulman To Board Of Directors

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) today announced the appointment of Amy Schulman to its board of directors.

Ironwood Pharmaceuticals To Present At J.P. Morgan Healthcare Conference

Ironwood Pharmaceuticals To Present At J.P. Morgan Healthcare Conference

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) will present a corporate update at the 35 th Annual J.

Ironwood And Allergan Report Topline Phase IIb Data Supporting Advancement Of Linaclotide Colonic Release-1 (CR1) In IBS-C

Ironwood And Allergan Report Topline Phase IIb Data Supporting Advancement Of Linaclotide Colonic Release-1 (CR1) In IBS-C

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) and Allergan plc (NYSE:AGN) announced today positive topline data from a Phase IIb clinical trial evaluating the investigational linaclotide colonic release-1...

Ironwood And Allergan Report Topline Phase IIb Data Supporting Further Investigation Of Linaclotide Colonic Release-2 (CR2) For Abdominal Pain In Non-Constipation Subtypes Of IBS

Ironwood And Allergan Report Topline Phase IIb Data Supporting Further Investigation Of Linaclotide Colonic Release-2 (CR2) For Abdominal Pain In Non-Constipation Subtypes Of IBS

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) and Allergan plc (NYSE:AGN) announced today topline data from a Phase IIb clinical trial evaluating an investigational linaclotide colonic release-2 (CR2)...

Ironwood Pharmaceuticals Announces Approval Of LINZESS® (linaclotide) In Japan For The Treatment Of Adults With IBS-C

Ironwood Pharmaceuticals Announces Approval Of LINZESS® (linaclotide) In Japan For The Treatment Of Adults With IBS-C

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) today announced that its partner, Astellas Pharma Inc.

Ironwood Highlights ZURAMPIC® (lesinurad) Phase III Extension Study Data At The American College Of Rheumatology 2016 Annual Meeting

Ironwood Highlights ZURAMPIC® (lesinurad) Phase III Extension Study Data At The American College Of Rheumatology 2016 Annual Meeting

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today presented efficacy and safety data from two Phase III extension studies of ZURAMPIC (lesinurad), as well as pooled analyses from the two extension studies and...

Ironwood Pharmaceuticals To Present At Stifel 2016 Healthcare Conference

Ironwood Pharmaceuticals To Present At Stifel 2016 Healthcare Conference

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) will present a corporate update at the Stifel 2016 Healthcare Conference on Wednesday, November 16th, 2016 at 8:00 a.

Ironwood Pharmaceuticals Provides Third Quarter 2016 Investor Update

Ironwood Pharmaceuticals Provides Third Quarter 2016 Investor Update

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a commercial biotechnology company, today provided an update on its third quarter 2016 results and recent business activities.

Ironwood Pharmaceuticals To Present At Credit Suisse 25th Annual Healthcare Conference

Ironwood Pharmaceuticals To Present At Credit Suisse 25th Annual Healthcare Conference

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) will present a corporate update at the Credit Suisse 25 th Annual Healthcare Conference on Tuesday, November 8th, 2016 at 2:00 p.

Ironwood Highlights Breadth Of Gout Research With Presentations At The American College Of Rheumatology 2016 Annual Meeting

Ironwood Highlights Breadth Of Gout Research With Presentations At The American College Of Rheumatology 2016 Annual Meeting

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced a series of oral and poster presentations to be presented at the upcoming American College of Rheumatology (ACR) Annual Meeting in Washington, D.

Ironwood Pharmaceuticals To Host Third Quarter 2016 Investor Update Call

Ironwood Pharmaceuticals To Host Third Quarter 2016 Investor Update Call

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced it will host its third quarter 2016 investor update conference call and webcast at 8:30 a.

Nine In Ten Physicians Agree Target Goal For Gout Is Imperative, Yet Half Of Patients Fail To Reach It, New Survey Shows

Nine In Ten Physicians Agree Target Goal For Gout Is Imperative, Yet Half Of Patients Fail To Reach It, New Survey Shows

A new survey conducted among primary care physicians and rheumatologists found that despite their overall agreement that gout is a serious and chronic medical condition with potential long-term consequences, patients remain...

ZURAMPIC® (lesinurad) Is Now Available In Pharmacies Throughout The United States. (Photo: Business Wire)

ZURAMPIC® (lesinurad) Is Now Available In Pharmacies Throughout The United States. (Photo: Business Wire)

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced that ZURAMPIC ® (lesinurad) is now available in pharmacies throughout the United States.

Ironwood Closes $150 Million Debt Refinancing

Ironwood Closes $150 Million Debt Refinancing

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) today announced the closing of a $150 million debt refinancing.

Ironwood Pharmaceuticals To Present At Morgan Stanley Global Healthcare Conference

Ironwood Pharmaceuticals To Present At Morgan Stanley Global Healthcare Conference

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) will participate in a fireside chat at the Morgan Stanley Global Healthcare Conference on Monday, September 12, 2016 at 9:55 a.

Ironwood Pharmaceuticals To Present At Wells Fargo 2016 Healthcare Conference

Ironwood Pharmaceuticals To Present At Wells Fargo 2016 Healthcare Conference

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) will present a corporate update at the Wells Fargo 2016 Healthcare Conference on Wednesday, September 7, 2016 at 2:20 p.

Ironwood Pharmaceuticals (IRWD): Today's Weak On High Volume Stock

Ironwood Pharmaceuticals (IRWD): Today's Weak On High Volume Stock

Trade-Ideas LLC identified Ironwood Pharmaceuticals (IRWD) as a weak on high relative volume candidate

Ironwood Pharmaceuticals Provides Second Quarter 2016 Investor Update

Ironwood Pharmaceuticals Provides Second Quarter 2016 Investor Update

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a commercial biotechnology company, today provided an update on its second quarter 2016 results and recent business activities.

Synergy Pharma Offers Lots of Synergies

Synergy Pharma Offers Lots of Synergies

I expect Allergan or another player to bid for SGYP soon.

Ironwood Pharmaceuticals To Host Second Quarter 2016 Investor Update Call

Ironwood Pharmaceuticals To Host Second Quarter 2016 Investor Update Call

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced it will host its second quarter 2016 investor update conference call and webcast at 4:30 p.

3 Stocks Pushing The Health Services Industry Higher

3 Stocks Pushing The Health Services Industry Higher

TheStreet highlights 3 stocks pushing the drugs industry higher today.